Gilead is laying off Arcellx employees in California and Maryland, with some cuts effective this year and the remainder ...
Acting Center for Drug Evaluation and Research Director Tracy Beth Høeg reportedly disagreed with staff who wanted to approve ...
Analysts and investors alike had been eagerly awaiting sales figures for Novo Nordisk’s Wegovy pill. The answer blew past ...
Robert F. Kennedy Jr.’s health department has consistently touted radical transparency as being key to its mission. Recent ...
The selloff in Eli Lilly's shares was “overdone,” according to RBC Capital Markets, which noted that the overall safety ...
Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its ...
As Q1 earnings arrive, three biotechs have big quarters ahead, with two—Amylyx and Neumora Therapeutics—betting at least ...
Despite the continued decline of Pfizer's COVID-19 products, shares stayed stable on Tuesday morning after the New York ...
The FDA is reportedly down to a handful of final candidates to lead CBER, with a potential selection expected in the coming ...
The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.
While some analysts may regard Vertex Pharmaceuticals’ first quarter results as “unremarkable,” BMO Capital Markets wrote on ...
A subsidiary of Indian drugmaker Hetero Group mistakenly packaged two types of antidepressants in packs of sertraline, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results